In a report released today, Edward White from H.C. Wainwright maintained a Hold rating on PharmaCyte Biotech (PMCB – Research Report). The company's shares closed last Tuesday at $2.36, close to its 52-week low of $1.79. According to TipRanks.com, White is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -16.5% and a 26.0% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and TRACON Pharmaceuticals. PharmaCyte Biotech has an analyst consensus of Hold.
https://www.tipranks.com/news/blurbs/h-c-wainwright-remains-a-hold-on-pharmacyte-biotech-pmcb-2?utm_source=advfn.com&utm_medium=referral
PharmaCyte Biotech (NASDAQ:PMCB)
Historical Stock Chart
From May 2022 to Jun 2022 Click Here for more PharmaCyte Biotech Charts.
PharmaCyte Biotech (NASDAQ:PMCB)
Historical Stock Chart
From Jun 2021 to Jun 2022 Click Here for more PharmaCyte Biotech Charts.